Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma

Yun Yen; Samuel So; Michal Rose; M. Wasif Saif; Edward Chu; Shwu Huey Liu; Angeline Foo; Zaoli Jiang; Tahmun Su; Yung Chi Cheng

Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma

Yun Yen, Samuel So, Michal Rose, M. Wasif Saif, Edward Chu, Shwu Huey Liu, Angeline Foo, Zaoli Jiang, Tahmun Su, Yung Chi Cheng

Research output: Contribution to journal › Article › peer-review

64 Citations (Scopus)

Abstract

PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

Original language	English
Pages (from-to)	4083-4092
Number of pages	10
Journal	Anticancer Research
Volume	29
Issue number	10
Publication status	Published - Oct 2009
Externally published	Yes

Keywords

Adjuvant therapy
Capecitabine
Hepatocellular carcinoma (HCC)
PHY906
Phase I/II

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{c515d279deaa43f5ab6c26531b414d77,

title = "Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma",

abstract = "PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.",

keywords = "Adjuvant therapy, Capecitabine, Hepatocellular carcinoma (HCC), PHY906, Phase I/II",

author = "Yun Yen and Samuel So and Michal Rose and Saif, {M. Wasif} and Edward Chu and Liu, {Shwu Huey} and Angeline Foo and Zaoli Jiang and Tahmun Su and Cheng, {Yung Chi}",

year = "2009",

month = oct,

language = "English",

volume = "29",

pages = "4083--4092",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "10",

}

TY - JOUR

T1 - Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma

AU - Yen, Yun

AU - So, Samuel

AU - Rose, Michal

AU - Saif, M. Wasif

AU - Chu, Edward

AU - Liu, Shwu Huey

AU - Foo, Angeline

AU - Jiang, Zaoli

AU - Su, Tahmun

AU - Cheng, Yung Chi

PY - 2009/10

Y1 - 2009/10

N2 - PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

AB - PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

KW - Adjuvant therapy

KW - Capecitabine

KW - Hepatocellular carcinoma (HCC)

KW - PHY906

KW - Phase I/II

UR - http://www.scopus.com/inward/record.url?scp=71949107671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71949107671&partnerID=8YFLogxK

M3 - Article

C2 - 19846955

AN - SCOPUS:71949107671

SN - 0250-7005

VL - 29

SP - 4083

EP - 4092

JO - Anticancer Research

JF - Anticancer Research

IS - 10

ER -

Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this